| Identification | Back Directory | [Name]
4′-Methoxy-N-methyl-3′-[[[3-[[2-[(3-methylbenzoyl)amino]ethyl]amino]phenyl]amino]sulfonyl]-N-(4-pyridinylmethyl)[1,1′-biphenyl]-3-carboxamide | [CAS]
2832067-72-6 | [Synonyms]
RTIOXA-43
4′-Methoxy-N-methyl-3′-[[[3-[[2-[(3-methylbenzoyl)amino]ethyl]amino]phenyl]amino]sulfonyl]-N-(4-pyridinylmethyl)[1,1′-biphenyl]-3-carboxamide | [Molecular Formula]
C37H37N5O5S | [MOL File]
2832067-72-6.mol | [Molecular Weight]
663.79 |
| Hazard Information | Back Directory | [Uses]
RTIOXA-43 is a orexin receptor agonist with EC50s of 24 nM and 24 nM for OX2 and OX1 receptors, respectively[1]. | [in vivo]
In adult (12 month) mice, peripheral injection of RTIOXA-43 improves wake time, reduced sleep time and sleep/wake fragmentation. In addition, RTIOXA-43 improves sleep/wake quality by decreasing the number of episodes and increasing the duration of these episodes[2]. | [IC 50]
OX1: 24 nM (EC50); OX2: 24 nM (EC50) | [References]
[1] Yanan Zhang, et al. Arylsulfoxamides as orexin receptor agonists. WO2022187231A1.
[2] Kotz, Catherine, et al.?Small Molecule Orexin Agonists Enhance Physical Activity, Cognition and Sleep Quality in Aged Mice. Obesity; Silver Spring Vol. 29, (Dec 2021): 163. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|